Shopping Cart 0
Cart Subtotal
USD 0

Eurofins Scientific SE (ERF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Eurofins Scientific SE (Eurofins) is a life sciences company, which provides a range of analytical testing services to clients in various industries. The company offers food and feed testing, biopharma services, pharma discovery services, genomic pharma services, pharma early development, pharma central laboratory, biopharma product testing, genomic services, agro-science services, product testing, forensic services, environmental testing and Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) services. Its analytical methods help in evaluating the safety, identity, composition, origin, authenticity and purity of biological products and substances. It harnesses its expertise in logistics and information technology to deliver a range of services. The company operates across Europe, North and South America, and Asia-Pacific. Eurofins is headquartered in Luxembourg.

Eurofins Scientific SE (ERF)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Eurofins Scientific to Acquire Testing Business from Exova 14

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 15

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 16

Viracor-IBT Labs Completes Acquisition Of Lab Operations Of National Institute of Transplantation 17

Venture Financing 18

Diatherix Secures Additional USD 0.53 Million In Venture Financing 18

Partnerships 19

GATC Biotech Enters into Agreement with University of Konstanz 19

Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 20

Qiagen Enters into Agreement with GATC Biotech 21

Merger 22

Bactimm Farma And Proxy Labs Merge To Form Sinensis Life Sciences 22

Equity Offering 23

Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares 23

Eurofins Scientific Raises USD333 Million in Private Placement of Shares 24

Debt Offering 25

Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds 25

Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024 26

Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023 27

Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023 28

Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022 29

Eurofins Prices Public Offering Of Bonds Due 2018 For USD 405.1 Million 30

Acquisition 31

Eurofins Acquires Covance from LabCorp 31

Eurofins Scientific to Acquire PHAST 33

Eurofins Scientific Acquires Selcia 34

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics 35

Eurofins Scientific to Acquire DiscoverX 37

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital 38

Eurofins GSC Lux Acquires ANA Laboratories 39

Eurofins Scientific Acquires Alphora Research 40

Eurofins Scientific to Acquire GATC Biotech 41

Amatsigroup Acquires Disposable-Lab 42

Eurofins Scientific to Acquire Villapharma Research 43

Amatsigroup Acquires Q-Biologicals 44

Eurofins Scientific Acquires Sinensis Life Sciences 45

Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 46

Eurofins Scientific Acquires QC Laboratories (QCL) 47

Amatsi Acquires Seps Pharma 48

Eurofins Scientific to Acquire SF Analytical Labs 49

Eurofins Genomics Acquires VBC-Biotech 50

Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million 51

Eurofins Scientific Acquires IDmyk 52

Eurofins Scientific Acquires 81% Stake In Agrisearch Services 53

Eurofins Discovery Services Acquires Majority Stake In Cerep 54

Eurofins Scientific Acquires Aros Applied Biotech, Genomic Solutions Provider 55

Proxy Labs Acquires MicroSafe Laboratories From Millipore 56

Eurofins Scientific SE-Key Competitors 57

Eurofins Scientific SE-Key Employees 58

Eurofins Scientific SE-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Recent Developments 63

Financial Announcements 63

Oct 23, 2018: Eurofins posts strong revenue growth in Q3 2018 (EUR 955m, +30.6% yoy including over 5% organic growth) and raises its objectives for 2019-2020-Revenues objective for 2020 now set at EUR 5bn 63

Jul 31, 2018: Eurofins delivers strong revenue, profitability and cash flow growth in H1 2018 65

Jun 26, 2018: Eurofins raises its revenues objectives for 2018 to EUR 3.8bn (4bn pro-forma), to 4.3bn for 2019 and to 4.7bn for 2020 71

Apr 24, 2018: Eurofins revenues grow +23% in Q1 2018 to EUR 839m 72

Mar 06, 2018: Eurofins exceeds its recently-upgraded 2017 objectives on a strong growth momentum and raises its objectives for 2018 73

Oct 24, 2017: After Strong NM 2017 Performance Eurofins Brings Forward by 1 Year, to 2019, Its EUR 4bn Annual Revenues Objective 80

Aug 30, 2017: Eurofins Reports Solid H1 2017 Results 81

Feb 28, 2017: Eurofins: Full Year 2016 Results 86

Product News 91

Oct 02, 2018: Eurofins BioPharma Product Testing Ireland opened the new extension in Dungarvan 91

Appendix 92

Methodology 92

About GlobalData 92

Contact Us 92

Disclaimer 92


List Of Figure

List of Figures

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Eurofins Scientific to Acquire Testing Business from Exova 14

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 15

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 16

Viracor-IBT Labs Completes Acquisition Of Lab Operations Of National Institute of Transplantation 17

Diatherix Secures Additional USD 0.53 Million In Venture Financing 18

GATC Biotech Enters into Agreement with University of Konstanz 19

Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 20

Qiagen Enters into Agreement with GATC Biotech 21

Bactimm Farma And Proxy Labs Merge To Form Sinensis Life Sciences 22

Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares 23

Eurofins Scientific Raises USD333 Million in Private Placement of Shares 24

Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds 25

Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024 26

Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023 27

Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023 28

Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022 29

Eurofins Prices Public Offering Of Bonds Due 2018 For USD 405.1 Million 30

Eurofins Acquires Covance from LabCorp 31

Eurofins Scientific to Acquire PHAST 33

Eurofins Scientific Acquires Selcia 34

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics 35

Eurofins Scientific to Acquire DiscoverX 37

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital 38

Eurofins GSC Lux Acquires ANA Laboratories 39

Eurofins Scientific Acquires Alphora Research 40

Eurofins Scientific to Acquire GATC Biotech 41

Amatsigroup Acquires Disposable-Lab 42

Eurofins Scientific to Acquire Villapharma Research 43

Amatsigroup Acquires Q-Biologicals 44

Eurofins Scientific Acquires Sinensis Life Sciences 45

Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 46

Eurofins Scientific Acquires QC Laboratories (QCL) 47

Amatsi Acquires Seps Pharma 48

Eurofins Scientific to Acquire SF Analytical Labs 49

Eurofins Genomics Acquires VBC-Biotech 50

Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million 51

Eurofins Scientific Acquires IDmyk 52

Eurofins Scientific Acquires 81% Stake In Agrisearch Services 53

Eurofins Discovery Services Acquires Majority Stake In Cerep 54

Eurofins Scientific Acquires Aros Applied Biotech, Genomic Solutions Provider 55

Proxy Labs Acquires MicroSafe Laboratories From Millipore 56

Eurofins Scientific SE, Key Competitors 57

Eurofins Scientific SE, Key Employees 58

Eurofins Scientific SE, Subsidiaries 59

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Eurofins Scientific SE, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Eurofins Scientific SE (Eurofins) is a life sciences company, which provides a range of analytical testing services to clients in various industries. The company offers food and feed testing, biopharma services, pharma discovery services, genomic pharma services, pharma early development, pharma central laboratory, biopharma product testing, genomic services, agro-science services, product testing, forensic services, environmental testing and Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) services. Its analytical methods help in evaluating the safety, identity, composition, origin, authenticity and purity of biological products and substances. It harnesses its expertise in logistics and information technology to deliver a range of services. The company operates across Europe, North and South America, and Asia-Pacific. Eurofins is headquartered in Luxembourg.

Eurofins Scientific SE (ERF)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Eurofins Scientific to Acquire Testing Business from Exova 14

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 15

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 16

Viracor-IBT Labs Completes Acquisition Of Lab Operations Of National Institute of Transplantation 17

Venture Financing 18

Diatherix Secures Additional USD 0.53 Million In Venture Financing 18

Partnerships 19

GATC Biotech Enters into Agreement with University of Konstanz 19

Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 20

Qiagen Enters into Agreement with GATC Biotech 21

Merger 22

Bactimm Farma And Proxy Labs Merge To Form Sinensis Life Sciences 22

Equity Offering 23

Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares 23

Eurofins Scientific Raises USD333 Million in Private Placement of Shares 24

Debt Offering 25

Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds 25

Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024 26

Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023 27

Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023 28

Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022 29

Eurofins Prices Public Offering Of Bonds Due 2018 For USD 405.1 Million 30

Acquisition 31

Eurofins Acquires Covance from LabCorp 31

Eurofins Scientific to Acquire PHAST 33

Eurofins Scientific Acquires Selcia 34

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics 35

Eurofins Scientific to Acquire DiscoverX 37

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital 38

Eurofins GSC Lux Acquires ANA Laboratories 39

Eurofins Scientific Acquires Alphora Research 40

Eurofins Scientific to Acquire GATC Biotech 41

Amatsigroup Acquires Disposable-Lab 42

Eurofins Scientific to Acquire Villapharma Research 43

Amatsigroup Acquires Q-Biologicals 44

Eurofins Scientific Acquires Sinensis Life Sciences 45

Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 46

Eurofins Scientific Acquires QC Laboratories (QCL) 47

Amatsi Acquires Seps Pharma 48

Eurofins Scientific to Acquire SF Analytical Labs 49

Eurofins Genomics Acquires VBC-Biotech 50

Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million 51

Eurofins Scientific Acquires IDmyk 52

Eurofins Scientific Acquires 81% Stake In Agrisearch Services 53

Eurofins Discovery Services Acquires Majority Stake In Cerep 54

Eurofins Scientific Acquires Aros Applied Biotech, Genomic Solutions Provider 55

Proxy Labs Acquires MicroSafe Laboratories From Millipore 56

Eurofins Scientific SE-Key Competitors 57

Eurofins Scientific SE-Key Employees 58

Eurofins Scientific SE-Locations And Subsidiaries 59

Head Office 59

Other Locations & Subsidiaries 59

Recent Developments 63

Financial Announcements 63

Oct 23, 2018: Eurofins posts strong revenue growth in Q3 2018 (EUR 955m, +30.6% yoy including over 5% organic growth) and raises its objectives for 2019-2020-Revenues objective for 2020 now set at EUR 5bn 63

Jul 31, 2018: Eurofins delivers strong revenue, profitability and cash flow growth in H1 2018 65

Jun 26, 2018: Eurofins raises its revenues objectives for 2018 to EUR 3.8bn (4bn pro-forma), to 4.3bn for 2019 and to 4.7bn for 2020 71

Apr 24, 2018: Eurofins revenues grow +23% in Q1 2018 to EUR 839m 72

Mar 06, 2018: Eurofins exceeds its recently-upgraded 2017 objectives on a strong growth momentum and raises its objectives for 2018 73

Oct 24, 2017: After Strong NM 2017 Performance Eurofins Brings Forward by 1 Year, to 2019, Its EUR 4bn Annual Revenues Objective 80

Aug 30, 2017: Eurofins Reports Solid H1 2017 Results 81

Feb 28, 2017: Eurofins: Full Year 2016 Results 86

Product News 91

Oct 02, 2018: Eurofins BioPharma Product Testing Ireland opened the new extension in Dungarvan 91

Appendix 92

Methodology 92

About GlobalData 92

Contact Us 92

Disclaimer 92


List Of Figure

List of Figures

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Eurofins Scientific SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Eurofins Scientific SE, Deals By Therapy Area, 2012 to YTD 2018 10

Eurofins Scientific SE, Medical Devices Deals, 2012 to YTD 2018 11

Eurofins Scientific SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Eurofins Scientific to Acquire Testing Business from Exova 14

Amatsigroup Acquires R&D Center from Pierre Fabre Labs 15

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 16

Viracor-IBT Labs Completes Acquisition Of Lab Operations Of National Institute of Transplantation 17

Diatherix Secures Additional USD 0.53 Million In Venture Financing 18

GATC Biotech Enters into Agreement with University of Konstanz 19

Diatherix Labs Enters into Research Agreement with Vanderbilt University Medical Center 20

Qiagen Enters into Agreement with GATC Biotech 21

Bactimm Farma And Proxy Labs Merge To Form Sinensis Life Sciences 22

Eurofins Scientific Raises USD347.1 Million in Private Placement of Shares 23

Eurofins Scientific Raises USD333 Million in Private Placement of Shares 24

Eurofins Scientific Raises USD464.7 Million in Public Offering of 3.25% Bonds 25

Eurofins Scientific Raises USD745.3 Million in Public Offering of 2.125% Bonds Due 2024 26

Eurofins Scientific Raises USD554 Million in Public Offering of 3.375% Bonds Due 2023 27

Eurofins Scientific Prices USD322 Million in Public Offering of 4.87% Bond Due 2023 28

Eurofins Scientific Raises USD579 Million in Public Offering of 2.25% Bond Due 2022 29

Eurofins Prices Public Offering Of Bonds Due 2018 For USD 405.1 Million 30

Eurofins Acquires Covance from LabCorp 31

Eurofins Scientific to Acquire PHAST 33

Eurofins Scientific Acquires Selcia 34

Eurofins Pharma Services Acquires Majority Stake in Advinus Therapeutics 35

Eurofins Scientific to Acquire DiscoverX 37

Eurofins Scientific Acquires Amatsigroup from Ekkio Capital 38

Eurofins GSC Lux Acquires ANA Laboratories 39

Eurofins Scientific Acquires Alphora Research 40

Eurofins Scientific to Acquire GATC Biotech 41

Amatsigroup Acquires Disposable-Lab 42

Eurofins Scientific to Acquire Villapharma Research 43

Amatsigroup Acquires Q-Biologicals 44

Eurofins Scientific Acquires Sinensis Life Sciences 45

Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 46

Eurofins Scientific Acquires QC Laboratories (QCL) 47

Amatsi Acquires Seps Pharma 48

Eurofins Scientific to Acquire SF Analytical Labs 49

Eurofins Genomics Acquires VBC-Biotech 50

Eurofins Scientific Completes Acquisition of Viracor-IBT Labs For USD255 Million 51

Eurofins Scientific Acquires IDmyk 52

Eurofins Scientific Acquires 81% Stake In Agrisearch Services 53

Eurofins Discovery Services Acquires Majority Stake In Cerep 54

Eurofins Scientific Acquires Aros Applied Biotech, Genomic Solutions Provider 55

Proxy Labs Acquires MicroSafe Laboratories From Millipore 56

Eurofins Scientific SE, Key Competitors 57

Eurofins Scientific SE, Key Employees 58

Eurofins Scientific SE, Subsidiaries 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Eurofins Scientific SE, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.